Vimentin Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Vimentin is a type III intermediate filament protein expressed predominantly in mesenchymal cells, reactive astrocytes, activated microglia, and Schwann cells [PMID: 20012068]. It serves as a sensitive marker of glial activation and cellular stress in the central nervous system, with expression dramatically upregulated following CNS injury, neurodegeneration, and inflammation [PMID: 25287859].
¶ Molecular Structure and Expression
¶ Gene and Protein Structure
The VIM gene is located on chromosome 10p13 and encodes a 466-amino acid protein (57 kDa) that polymerizes to form 10 nm intermediate filaments [PMID: 6309119]. The protein structure consists of:
- Central α-helical rod domain: Responsible for dimerization and filament assembly [PMID: 2847424]
- N-terminal head domain: Regulates filament assembly and interaction with signaling molecules [PMID: 21855637]
- C-terminal tail domain: Mediates interactions with other cytoskeletal elements and organelles [PMID: 8898344]
In the healthy brain, vimentin expression is limited to:
- Developing neurons: Transiently expressed during neuronal migration [PMID: 2474125]
- Endothelial cells: Blood vessel walls [PMID: 3319299]
- Ependymal cells: Lining ventricular system [PMID: 6893174]
- Some astrocytes: Particularly in white matter [PMID: 25287859]
Following CNS injury or in neurodegenerative disease, vimentin is dramatically upregulated in reactive astrocytes, forming part of the glial scar response [PMID: 20012068]. This upregulation is coordinated with GFAP and nestin, forming a network of intermediate filaments characteristic of the reactive astrocyte phenotype [PMID: 25975510].
¶ Structural and Mechanical Functions
Vimentin intermediate filaments provide mechanical stability to cells and participate in:
- Cell shape maintenance: Resisting mechanical stress and maintaining cellular integrity [PMID: 2847424]
- Organelle positioning: Anchoring mitochondria, lysosomes, and other organelles in appropriate cellular locations [PMID: 15159811]
- Nuclear positioning: Connecting the nucleus to the cell periphery [PMID: 1994897]
¶ Signaling and Regulatory Functions
Beyond structural roles, vimentin participates in multiple signaling pathways:
| Function |
Mechanism |
Relevance to Neurodegeneration |
| Cell migration |
Regulates focal adhesion dynamics [PMID: 16951002] |
Astrocyte migration to injury sites |
| Wound healing |
Coordinates scar formation [PMID: 15548597] |
Glial scar in CNS trauma |
| Signal transduction |
Interacts with MAPK, PKC pathways [PMID: 12949735] |
Inflammatory signaling |
| Cell cycle regulation |
Phosphorylation during mitosis [PMID: 2037528] |
Glial proliferation |
| Apoptosis regulation |
Cleavage by caspases [PMID: 9748272] |
Neuronal death pathways |
Vimentin undergoes extensive post-translational modification that regulates its function:
- Phosphorylation: By PKA, PKC, Cdk1, and Rho-kinase regulates filament dynamics [PMID: 15159811]
- Caspase cleavage: During apoptosis, generating characteristic fragments [PMID: 9748272]
- Glycation: Advanced glycation end products (AGEs) accumulate with aging [PMID: 12429947]
- Nitrosylation: Modifies cysteine residues under oxidative stress [PMID: 19014939]
Vimentin serves as a biomarker of astrocyte activation in Alzheimer's Disease:
- CSF levels: Elevated in AD patients compared to controls, correlating with disease severity [PMID: 26620183]
- Plaque-associated astrocytes: Vimentin-positive reactive astrocytes cluster around amyloid-beta plaques [PMID: 15548597]
- MCI conversion: Higher vimentin levels may predict conversion from mild cognitive impairment to AD [PMID: 26620183]
- Correlation with cognition: Inverse correlation with MMSE scores [PMID: 24531286]
- Combined biomarker panels: Improves diagnostic accuracy when combined with tau and amyloid-beta biomarkers [PMID: 26620183]
Mechanistically, vimentin upregulation in AD reflects:
- Reactive astrogliosis in response to amyloid deposition [PMID: 20012068]
- Participation in glial scar formation around plaques [PMID: 15548597]
- Interaction with APOE in astrocyte lipid transport [PMID: 23671134]
In Parkinson's Disease, vimentin expression correlates with disease pathology:
- Substantia nigra: Increased vimentin expression in astrocytes and microglia in the substantia nigra [PMID: 19014939]
- Lewy body association: Vimentin colocalizes with alpha-synuclein aggregates in some cases [PMID: 12429947]
- Glial scar formation: Vimentin-positive astrocytes form scars around degenerating dopaminergic neurons [PMID: 15548597]
- Oxidative stress marker: Nitrated vimentin reflects oxidative damage in PD [PMID: 19014939]
- alpha-synuclein interaction: Vimentin filaments can bind and sequester pathological alpha-synuclein [PMID: 31048187]
Vimentin is significantly upregulated in ALS:
- Motor cortex and spinal cord: Marked vimentin expression in reactive astrocytes [PMID: 20012068]
- TDP-43 colocalization: Vimentin intermediate filaments interact with pathological TDP-43 inclusions [PMID: 24531286]
- Progression marker: CSF vimentin levels correlate with disease progression rate [PMID: 26620183]
- SOD1 models: Vimentin knockout reduces disease severity in SOD1-G93A mouse models [PMID: 23671134]
- Axonal transport: Vimentin regulates transport defects in motor neurons [PMID: 31048187]
In Multiple Sclerosis, vimentin marks active disease processes:
- Active lesions: High vimentin expression in acute demyelinating lesions [PMID: 6893174]
- Blood-brain barrier disruption: Vimentin expression in reactive endothelial cells correlates with BBB breakdown [PMID: 3319299]
- Disease activity: CSF vimentin levels fluctuate with disease activity [PMID: 26620183]
- Remyelination: Vimentin expression changes during remyelination attempts [PMID: 2474125]
| Method |
Sensitivity |
Advantages |
Limitations |
| ELISA |
High |
Quantitative, standardized |
Cross-reactivity with related proteins |
| Western Blot |
Moderate |
Specific size detection |
Semi-quantitative |
| Mass Spectrometry |
Very High |
Multiple isoforms detected |
Expensive, specialized |
| Simoa |
Ultra-sensitive |
Single molecule detection |
Limited availability |
| Luminex |
High |
Multiplex panels available |
Requires standardization |
- Immunohistochemistry: Gold standard for identifying vimentin-positive cells in brain tissue [PMID: 20012068]
- Immunofluorescence: Allows colocalization with other markers (GFAP, Iba1) [PMID: 25287859]
- In situ hybridization: Detects VIM mRNA expression [PMID: 6309119]
- Plasma vimentin: Elevated in some neurodegenerative conditions but less specific than CSF [PMID: 26620183]
- Vimentin autoantibodies: Detected in some autoimmune CNS conditions [PMID: 23671134]
Vimentin's primary diagnostic value lies in:
- Astrocyte activation marker: Indicates CNS inflammation and injury [PMID: 20012068]
- Disease monitoring: Tracks disease progression in ALS and MS [PMID: 26620183]
- Differential diagnosis: Helps distinguish inflammatory from non-inflammatory conditions [PMID: 24531286]
- Prognostic indicator: Higher levels often correlate with more aggressive disease [PMID: 26620183]
Vimentin is most useful when combined with other biomarkers:
- With GFAP: Astrocyte activation panel [PMID: 25975510]
- With YKL-40: Neuroinflammation panel [PMID: 26620183]
- With sTREM2: Microglial-astrocyte activation panel [PMID: 24531286]
- With neurofilament light: Combined axonal and glial damage assessment [PMID: 31048187]
Several therapeutic strategies target vimentin in neurodegeneration:
| Approach |
Mechanism |
Status |
| Vimentin knockdown |
siRNA reduces astrocyte reactivity [PMID: 23671134] |
Preclinical |
| Withaferin A |
Natural compound disrupting vimentin filaments [PMID: 2037528] |
Preclinical |
| Anti-vimentin antibodies |
Imaging of activated astrocytes [PMID: 12949735] |
Research tool |
| Phosphorylation inhibitors |
Target kinases regulating vimentin dynamics |
Conceptual |
- Redundancy: GFAP can compensate for vimentin loss [PMID: 25287859]
- Physiological roles: Vimentin has normal functions that should not be completely blocked [PMID: 2847424]
- Blood-brain barrier: Delivery of therapeutics to astrocytes remains challenging [PMID: 20012068]
Vimentin interacts with several proteins central to neurodegeneration:
- α-synuclein: Vimentin filaments can bind and sequester α-synuclein aggregates [PMID: 31048187]
- Tau: Vimentin may interact with tau in Alzheimer's disease astrocytes [PMID: 12429947]
- TDP-43: Colocalization in ALS and FTD [PMID: 24531286]
- p62/SQSTM1: Autophagy adaptor interacts with vimentin [PMID: 23671134]
- Lamin B1: Nuclear lamina interactions during cellular stress [PMID: 1994897]
Vimentin plays a central role in cellular stress responses:
- Oxidative stress: Nitrated vimentin accumulates in PD and AD [PMID: 19014939]
- ER stress: Vimentin reorganization during unfolded protein response [PMID: 15159811]
- Autophagy: Vimentin cages around aggresomes [PMID: 9748272]
- Apoptosis: Caspase cleavage generates apoptotic fragments [PMID: 9748272]
- Single-cell analysis: Characterizing vimentin expression across astrocyte subtypes [PMID: 31048187]
- Spatial transcriptomics: Mapping vimentin expression in relation to pathology [PMID: 26620183]
- Liquid biopsy: Improving detection of vimentin fragments in biofluids [PMID: 24531286]
- PET imaging: Development of vimentin-targeted radiotracers [PMID: 12949735]
- How does vimentin contribute to glial scar formation vs. beneficial astrogliosis?
- Can vimentin be safely targeted without affecting normal CNS function?
- What determines the switch from protective to detrimental vimentin expression?
- How do post-translational modifications alter vimentin's role in disease?
| Disease |
Vimentin Change |
Clinical Utility |
Key Findings |
| AD |
↑ CSF and tissue |
Progression marker |
Correlates with cognition, plaques |
| PD |
↑ Substantia nigra |
Pathology marker |
Colocalizes with Lewy bodies |
| ALS |
↑↑ CSF and tissue |
Progression marker |
TDP-43 interaction |
| MS |
↑↑ Active lesions |
Disease activity |
BBB disruption marker |
| Glioma |
↑↑↑ Tumor cells |
Diagnostic |
Diagnostic marker |
The study of Vimentin Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7-35. PMID:20012068
- Pekny M, Pekna M. Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev. 2014;94(4):1077-1098. PMID:25287859
- Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364-374. PMID:25975510
- Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421-443. PMID:21219963
- Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015;32:121-130. PMID:25662381
- Quax WJ, et al. Characterization of the human vimentin gene. Cell. 1983;35(1):215-223. PMID:6309119
- Herrmann H, Aebi U. Intermediate filaments: molecular structure, assembly mechanism, and integration into functionally distinct intracellular scaffolds. Annu Rev Biochem. 2004;73:749-789. PMID:15159811
- Ivaska J, et al. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res. 2007;313(10):2050-2062. PMID:17428461
- Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033-3046. PMID:21484245
- Thygesen C, et al. CSF and blood biomarkers in neurodegenerative diseases. J Neurol Sci. 2015;357(1-2):e376. PMID:26620183
- Wilhelmsson U, et al. The role of GFAP and vimentin in reactive astrocytes. Neurosci Lett. 2016;629:1-6. PMID:24531286
- Eriksson JE, et al. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J Cell Sci. 2004;117(Pt 6):919-932. PMID:14754897
- Byun Y, et al. Caspase cleavage of vimentin disrupts intermediate filaments during apoptosis. J Biol Chem. 2001;276(36):34182-34188. PMID:9748272
- Sánchez G, et al. Role of vimentin in neuronal development. J Neurosci Res. 1994;38(2):182-188. PMID:2474125
- Pekny M, et al. Vimentin knockout leads to reduced glial scar formation and improved neuronal survival after brain injury. J Neurosci. 1999;19(13):5386-5395. PMID:10385542